|
WO2021067946A1
|
|
Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
|
|
WO2021067569A1
|
|
Substituted 1, 6-naphthyridine inhibitors of cdk5
|
|
WO2021062089A1
|
|
Xanthine cb1 inhibitors
|
|
WO2020210626A1
|
|
Spray-dried formulation of a pyridazinone trpc5 inhibitor
|
|
WO2020191056A1
|
|
Pyridazinones and methods of use thereof
|
|
CA3113236A1
|
|
Pyridazinones and methods of use thereof
|
|
WO2020206623A1
|
|
Crystal forms
|
|
WO2019173327A1
|
|
Imidazodiazepinediones and methods of use thereof
|
|
CA3075727A1
|
|
Pyridazinones and methods of use thereof
|
|
WO2019028308A1
|
|
Benzimidazoles and aza-benzimidazoles, and methods of use thereof
|
|
WO2019028309A1
|
|
Azaindoles and methods of use thereof
|
|
AU2015292582A1
|
|
Collagen IV replacement
|
